Goldman snatches Bristol-Myers deal

Goldman Sachs has beaten rivals JP Morgan and Lehman Brothers to a mandate to sell the $800m (€606m) consumer medicines unit of Bristol-Myers Squibb, the US pharmaceuticals giant.

According to a report on Bloomberg, citing unnamed people familiar with the situation, Goldman will sell the business to leave Bristol-Myers to focus on its core pharmaceuticals business.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump